AFP and hepatocellular carcinoma: Recently, the REACH‐2 trial demonstrated that ramucirumab (RAM) showed survival benefit in patients with u‐HCC progressing on SOR and baseline alpha fetoprotein (AFP) level of ≥400 ng/mL.10